Brief: Bellicum Pharmaceuticals says dosed first patient with BPX-601
21/02/2017 12:06
Feb 21 (Reuters) - Bellicum Pharmaceuticals Inc BLCM.O :
* Bellicum Pharmaceuticals Inc- dosed first patient with
BPX-601, first car t-cell product candidate to enter clinical
studies
Source text for Eikon: ID:nGNXNQHAQa
Further company coverage: BLCM.O
((bangalore.newsroom@thomsonreuters.com;))
Recent news on Bellicum Pharmaceuticals
See all newsBrief: Bellicum Pharmaceuticals- In Connection With Dissolution And Plan Of Dissolution, On February 23, Richard A. Fair Resigned As President And Co's CEO
Brief: Bellicum Pharmaceuticals Says Board Approved Liquidation And Dissolution Of Co In Connection With Approval Of Asset Purchase Agreement
Brief: Bellicum Pharmaceuticals Initiated A 12 Stock Split On Dec 8, 2022
Brief: Bellicum Reports Third Quarter 2022 Financial Results And Provides Operational Update
Bellicum Pharmaceuticals Inc expected to post a loss of 64 cents a share - Earnings Preview